157 related articles for article (PubMed ID: 29870600)
1. Analytical Aspects of Biopharmaceuticals and their Study by Mass Spectrometry.
David V; Borbala D; Laroly V; Laszlo D; Istvan A; Imre K; Krisztina L
Acta Pharm Hung; 2016; 86(4):141-150. PubMed ID: 29870600
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
3. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.
Háda V; Bagdi A; Bihari Z; Timári SB; Fizil Á; Szántay C
J Pharm Biomed Anal; 2018 Nov; 161():214-238. PubMed ID: 30205300
[TBL] [Abstract][Full Text] [Related]
4. Top-down mass spectrometry and hydrogen/deuterium exchange for comprehensive structural characterization of interferons: implications for biosimilars.
Pan J; Borchers CH
Proteomics; 2014 May; 14(10):1249-58. PubMed ID: 24574185
[TBL] [Abstract][Full Text] [Related]
5. Analysis of biological therapeutic agents and biosimilars.
Phinney K
Anal Bioanal Chem; 2014 Oct; 406(26):6539. PubMed ID: 25190012
[No Abstract] [Full Text] [Related]
6. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
7. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical characterization of biopharmaceuticals.
Parr MK; Montacir O; Montacir H
J Pharm Biomed Anal; 2016 Oct; 130():366-389. PubMed ID: 27324698
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
10. Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity.
Yang Y; Liu F; Franc V; Halim LA; Schellekens H; Heck AJ
Nat Commun; 2016 Nov; 7():13397. PubMed ID: 27824045
[TBL] [Abstract][Full Text] [Related]
11. Integrated Bottom-Up and Top-Down Liquid Chromatography-Mass Spectrometry for Characterization of Recombinant Human Growth Hormone Degradation Products.
Wang YA; Wu D; Auclair JR; Salisbury JP; Sarin R; Tang Y; Mozdzierz NJ; Shah K; Zhang AF; Wu SL; Agar JN; Love JC; Love KR; Hancock WS
Anal Chem; 2017 Dec; 89(23):12771-12777. PubMed ID: 29096433
[TBL] [Abstract][Full Text] [Related]
12. MS in the analysis of biosimilars.
Singleton CA
Bioanalysis; 2014; 6(12):1627-37. PubMed ID: 25077624
[TBL] [Abstract][Full Text] [Related]
13. N-glycan Analysis in Molecular Medicine: Innovator and Biosimilar Protein Therapeutics.
Borza B; Hajba L; Guttman A
Curr Mol Med; 2020; 20(10):828-839. PubMed ID: 33272172
[TBL] [Abstract][Full Text] [Related]
14. Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.
Kaltashov IA; Bobst CE; Abzalimov RR; Berkowitz SA; Houde D
J Am Soc Mass Spectrom; 2010 Mar; 21(3):323-37. PubMed ID: 19963397
[TBL] [Abstract][Full Text] [Related]
15. A View on the Importance of "Multi-Attribute Method" for Measuring Purity of Biopharmaceuticals and Improving Overall Control Strategy.
Rogers RS; Abernathy M; Richardson DD; Rouse JC; Sperry JB; Swann P; Wypych J; Yu C; Zang L; Deshpande R
AAPS J; 2017 Nov; 20(1):7. PubMed ID: 29192343
[TBL] [Abstract][Full Text] [Related]
16. Identification of Low-Level Product-Related Variants in Filgrastim Products Presently Available in Highly Regulated Markets.
Hausberger A; Lamanna WC; Hartinger M; Seidl A; Toll H; Holzmann J
BioDrugs; 2016 Jun; 30(3):233-42. PubMed ID: 27026103
[TBL] [Abstract][Full Text] [Related]
17. Application of new analytical technology to the production of a "well-characterized biological".
Apffel A; Chakel J; Udiavar S; Swedberg S; Hancock WS; Souders C; Pungor E
Dev Biol Stand; 1998; 96():11-25. PubMed ID: 9890511
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of molecular targets of natural products by mass spectrometry.
Cheng KW; Wong CC; Wang M; He QY; Chen F
Mass Spectrom Rev; 2010; 29(1):126-55. PubMed ID: 19319922
[TBL] [Abstract][Full Text] [Related]
19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
20. Characterization and QC of biopharmaceuticals by MS-based 'multi-attribute method': advantages and challenges.
Zhang Y; Guo J
Bioanalysis; 2017 Mar; 9(6):499-502. PubMed ID: 28207284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
